Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kiniksa Pharmaceuticals International Plc (KNSA)

Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,409,304
  • Shares Outstanding, K 75,796
  • Annual Sales, $ 423,240 K
  • Annual Income, $ -43,190 K
  • EBIT $ 38 M
  • EBITDA $ 40 M
  • 60-Month Beta 0.06
  • Price/Sales 5.73
  • Price/Cash Flow N/A
  • Price/Book 6.33

Options Overview Details

View History
  • Implied Volatility 63.56% (-6.22%)
  • Historical Volatility 41.20%
  • IV Percentile 42%
  • IV Rank 38.27%
  • IV High 111.76% on 04/16/25
  • IV Low 33.68% on 08/22/25
  • Expected Move (DTE 7) 1.28 (2.85%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 11,468
  • Open Int (30-Day) 12,788
  • Expected Range 43.44 to 45.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.29
  • Number of Estimates 3
  • High Estimate 0.41
  • Low Estimate 0.18
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +341.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.02 +20.77%
on 01/15/26
45.50 -1.74%
on 02/12/26
+3.59 (+8.73%)
since 01/12/26
3-Month
37.02 +20.77%
on 01/15/26
45.50 -1.74%
on 02/12/26
+4.13 (+10.18%)
since 11/12/25
52-Week
18.25 +144.92%
on 04/09/25
45.50 -1.74%
on 02/12/26
+25.43 (+131.90%)
since 02/12/25

Most Recent Stories

More News
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

LGND : 181.65 (-2.32%)
KNSA : 44.71 (-0.60%)
ASND : 218.10 (-1.53%)
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...

OTLK : 0.4410 (-6.05%)
KNSA : 44.71 (-0.60%)
CRMD : 7.36 (-0.94%)
PHAR : 15.30 (-1.73%)
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation.The...

KNSA : 44.71 (-0.60%)
CRMD : 7.36 (-0.94%)
CPRX : 23.60 (-1.38%)
PHAR : 15.30 (-1.73%)
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Shares of Precigen, Inc. PGEN have skyrocketed 144.4% in August so far, following the company's announcement of the FDA approval for Papzimeos (zopapogene imadenovec-drba) for the treatment of adults...

KNSA : 44.71 (-0.60%)
PGEN : 4.74 (-3.46%)
CRMD : 7.36 (-0.94%)
INO : 1.5800 (-1.86%)
Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas

For Immediate ReleaseChicago, IL – August 14, 2025 – Stocks in this week’s article are Modine Manufacturing Co. MOD, Tutor Perini Corp. TPC, Kiniksa Pharmaceuticals International plc KNSA, Life360...

KNSA : 44.71 (-0.60%)
MOD : 215.45 (-1.85%)
TPC : 81.73 (-3.93%)
LIF : 50.34 (-4.53%)
ESEA : 55.56 (-3.31%)
5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties

U.S. stock markets have maintained their northward journey in the first half of August despite tariff and trade-related uncertainties and the Fed’s indecision regarding the timing of the first interest...

KNSA : 44.71 (-0.60%)
MOD : 215.45 (-1.85%)
TPC : 81.73 (-3.93%)
LIF : 50.34 (-4.53%)
ESEA : 55.56 (-3.31%)
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

KNSA : 44.71 (-0.60%)
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The demand for healthcare products and services typically holds up very well regardless...

KNSA : 44.71 (-0.60%)
VRTX : 465.02 (+0.82%)
AGN.AX : 0.260 (unch)
ABBV : 227.50 (+2.99%)
Insider Sale: CHIEF FINANCIAL OFFICER of $KNSA (KNSA) Sells 1,123 Shares

Mark Ragosa, the CHIEF FINANCIAL OFFICER of $KNSA ($KNSA), sold 1,123 shares of the company on 12-05-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.7%...

KNSA : 44.71 (-0.60%)
Insider Sale: CHIEF ACCOUNTING OFFICER of $KNSA (KNSA) Sells 9 Shares

Michael R Megna, the CHIEF ACCOUNTING OFFICER of $KNSA ($KNSA), sold 9 shares of the company on 11-29-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0%...

KNSA : 44.71 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa Pharmaceuticals International plc is based in LONDON.

See More

Key Turning Points

3rd Resistance Point 47.64
2nd Resistance Point 46.57
1st Resistance Point 45.64
Last Price 44.71
1st Support Level 43.64
2nd Support Level 42.57
3rd Support Level 41.64

See More

52-Week High 45.50
Last Price 44.71
Fibonacci 61.8% 35.09
Fibonacci 50% 31.88
Fibonacci 38.2% 28.66
52-Week Low 18.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar